A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19 requiring admission to the intensive care unit (ICU) through Day 29.

Official Title
-----------------
A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Biological: Convalescent anti-SARS-CoV-2 MBT Plasma
* Drug: Standard Medical Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized male or female subjects of ≥ 18 years of age at time of Screening who are being treated in the intensive care unit (ICU) for COVID-19 for not longer than 48 hours or for whom a decision has been made that COVID-19 disease severity warrants ICU admission. Subject (or a legal representative or a nearest relative or a relative by marriage, as appropriate) provides informed consent (ICF) prior to initiation of any study procedures. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR), or other commercial or public health assay in any specimen during the current hospital admission prior to randomization. Illness (symptoms) of any duration, and the following: Radiographic infiltrates by imaging (chest x-ray, computerized tomography [CT] scan, etc.), and Requiring mechanical ventilation and/or supplemental oxygen Subjects with no limitation of therapeutic effort (decision on the status and future of the subject). Female subjects of child-bearing potential must have a negative test for pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at Screening/Baseline Visit. Exclusion Criteria: Clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may place the subject at undue medical risk. The subject has had a known serious anaphylactic reaction to blood, any blood-derived or plasma product or methylene blue. A medical condition in which the infusion of additional fluid is contraindicated. Shock unresponsive to fluid challenge and/or multiple vasopressors and accompanied by multiorgan failure considered by the Principal Investigator not able to be reversed.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Convalescent anti-SARS-CoV-2 MBT Plasma + SMT<br>Participants will receive 2 consecutive transfusions of 200 to 250 milliliters (ml) of ABO-compatible convalescent plasma with each unit of plasma, obtained from the same convalescent donor, which will be administered on Day 1 using standard procedures for administration of fresh frozen plasma. Participants weighing less than 45 kilograms (kg) will receive two transfusions of 10 ml of convalescent plasma per kilogram of body weight with each unit of plasma obtained from the same convalescent donor. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29. | Biological: Convalescent anti-SARS-CoV-2 MBT Plasma<br>* Intravenous infusion.<br>Drug: Standard Medical Treatment<br>* SMT<br>|
| Active Comparator: Standard Medical Treatment<br>Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29. | Drug: Standard Medical Treatment<br>* SMT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-Cause Mortality Rate |  | Up to Day 29 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in National Early Warning Score (NEWS) |  | Day 1 through Day 29 | 
| Time to Clinical Response as Assessed by NEWS ≤ 2 Maintained for 24 hours |  | Day 1 through Day 29 | 
| Time to Hospital Discharge |  | Day 1 through Day 29 | 
| Time to ICU Discharge |  | Day 1 through Day 29 | 
| Duration of All Oxygen Use |  | Day 1 through Day 29 | 
| Duration of Mechanical Ventilation |  | Day 1 through Day 29 | 
| Absolute Value Change from Baseline in Ordinal Scale |  | Day 1 through Day 29 | 
| Mean Change from Baseline in Ordinal Scale |  | Day 1 through Day 29 | 
| Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale |  | Day 15 and Day 29 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronavirus Disease, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2